Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989;99(3):371-3.
doi: 10.1007/BF00445560.

Radial-arm maze performance in rats is impaired by a combination of nicotinic-cholinergic and D2 dopaminergic antagonist drugs

Affiliations

Radial-arm maze performance in rats is impaired by a combination of nicotinic-cholinergic and D2 dopaminergic antagonist drugs

S R McGurk et al. Psychopharmacology (Berl). 1989.

Abstract

Performance on the radial-arm maze depends on the integrity of both cholinergic and dopaminergic systems. We have previously found that administration of either the nicotinic-cholinergic antagonist, mecamylamine, or the muscarinic-cholinergic antagonist, scopolamine, impairs choice accuracy in the radial-arm maze. Co-administration of the dopaminergic antagonist, haloperidol, ameliorated the performance deficit caused by scopolamine but exacerbated the deficit caused by mecamylamine. Furthermore, antagonism of the effect of scopolamine is due specifically to blockade of D1 receptors. In the present experiment behaviorally subthreshold doses of mecamylamine and the D2 antagonist raclopride impaired maze performance when administered together. No interactive effects were observed between mecamylamine and the D1 antagonist SCH 23390. Although several of the drug treatments studied significantly increased choice latency, an index of motor behavior, there was no perfect relationship between choice accuracy and choice latency. These data indicate that nicotinic-cholinergic and muscarinic-cholinergic systems interact selectively and differentially with D1 and D2 dopaminergic systems.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Pharmacol Biochem Behav. 1987 Jan;26(1):1-6 - PubMed
    1. Neurosci Biobehav Rev. 1988 Summer;12(2):169-75 - PubMed
    1. Pharmacol Biochem Behav. 1983 Jan;18(1):7-12 - PubMed
    1. Behav Neural Biol. 1988 Sep;50(2):240-5 - PubMed
    1. Pharmacol Biochem Behav. 1980 Apr;12(4):595-602 - PubMed

Publication types

LinkOut - more resources